Last updated: 2026-09-16 10:31:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Akebia Therapeutics, Inc. (AKBA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.91, with a market capitalisation of $266.83M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.81 to $3.20. This page covers its latest market performance, valuation, price trends and company information.
$266.83M | |
$0.91 | |
$31.00 | |
$0.24 | |
$0.90 | |
200.00 | |
6.16M | |
-- | |
$3.20 | |
$0.81 | |
-- | |
-- |
Akebia Therapeutics, Inc. (AKBA) is trading at $0.91 in pre-market trading as of 2026-09-16 08:02:00, up 1.22% ($0.01) from the previous close of $0.90
Pre-market trading shows how investors are pricing AKBA before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Akebia Therapeutics, Inc. (AKBA) moved from $0.97 to $0.91, representing a decline of 6.23% ($0.06).
The stock traded between $0.90 and $1.05 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 6.00 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 4.2%
AKBA is currently trading at $0.91, placing it 4.2% of the way from its 52-week low of $0.81 to its 52-week high of $3.20. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 194 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Akebia Therapeutics, Inc. (AKBA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.